Disease Info Card

Dystrophia Myotonica 2

Information about Dystrophia Myotonica 2: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Dystrophia Myotonica 2

Most recent studies have shown that Dystrophia Myotonica 2 shares some biological mechanisms with cardiovascular-diseases, complications-of-diabetes-mellitus, diabetes-mellitus, diabetes-mellitus-insulin-dependent, diabetes-mellitus-non-insulin-dependent, dystrophy, heart-diseases, hyperglycemia, hypertensive-disease, impaired-glucose-tolerance, insulin-resistance, insulin-sensitivity, kidney-diseases, metabolic-syndrome-x, muscle-weakness, myopathy, myotonic-disorders, myotonic-dystrophy, obesity, weakness.

Among the many pathways, these few ones have gauged particular interests from scientists studying Dystrophia Myotonica 2, and have been seen in publications frequently: Aging, Angiogenesis, Cardiac Conduction, Coagulation, Cognition, Excretion, Glomerular Filtration, Gluconeogenesis, Glucose Homeostasis, Insulin Secretion, Interphase, Localization, Pathogenesis, Regeneration, Rna Processing, Secretion, Segmentation, Translation, Transport, Vasodilation

Quite a number of genes have been found to play important roles in Dystrophia Myotonica 2, such as ACE, ADIPOQ, ALB, CCT3, CD55, CELF1, CLCN1, CNBP, CRP, DMPK, IDE, IL6, INS, INSR, LEP, MBNL1, PPARG, TG, TNF, ZNF273. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.